Incannex Healthcare (NASDAQ: IXHL) highlights clinical and capital focus in update

Rhea-AI Filing Summary

Incannex Healthcare Inc. filed a current report to let investors know it has issued a new shareholder update. On October 30, 2025, the company provided an overview for shareholders that highlights its clinical progress, capital discipline, and end‑of‑year 2025 strategic focus.

The details of this update are contained in a press release attached as Exhibit 99.1 to the report, which is incorporated by reference into the filing. The company’s common stock continues to trade on the Nasdaq Stock Market under the symbol IXHL.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001873875 0001873875 2025-10-30 2025-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

Incannex Healthcare Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41106		93-2403210
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia		Not applicable
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, including Area Code: +61 409 840 786

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Stock, $0.0001 par value per share		IXHL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 30, 2025, Incannex Healthcare Inc. Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Incannex Healthcare Inc., dated October 30, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Incannex Healthcare Inc.
Date: October 30, 2025		/s/ Joel Latham
	Name:	Joel Latham
	Title:	Chief Executive Officer and President

2

FAQ

What event does Incannex Healthcare Inc. (IXHL) report in this Form 8-K?

Incannex Healthcare Inc. reports that on October 30, 2025, it provided a shareholder update highlighting clinical progress, capital discipline, and its end‑of‑year 2025 strategic focus.

How did Incannex Healthcare Inc. (IXHL) communicate its shareholder update?

The shareholder update was communicated through a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference into the disclosure.

What key themes are emphasized in Incannex Healthcare’s October 30, 2025 shareholder update?

The update emphasizes clinical progress in the company’s programs, its approach to capital discipline, and its strategic focus through the end of 2025.

Where can investors find the full details of the Incannex Healthcare (IXHL) shareholder update?

Investors can find the full details in the press release dated October 30, 2025, filed as Exhibit 99.1 to the Form 8-K.

Which exchange lists Incannex Healthcare Inc. common stock and under what symbol?

Incannex Healthcare Inc. common stock is listed on The Nasdaq Stock Market LLC under the trading symbol IXHL.

Does this Form 8-K from Incannex Healthcare include financial statements?

The report lists Exhibit 99.1 as a press release and Exhibit 104 as the cover page interactive data file; it does not list separate financial statements as exhibits.